Evidence map›Paper›PMID 27123812›Full record

ReviewCurrent opinion in structural biology2016

Designing helical peptide inhibitors of protein-protein interactions.

Raheleh Rezaei Araghi, Amy E Keating

Abstract readReview
In one paragraph

Review in Current opinion in structural biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Expression of Lanthipeptides in Human Cells.bioRxiv : the preprint server for biology · 2023
    Article
  5. Review
  6. Article
  7. Will Peptides Help to Stop COVID-19?Biochemistry. Biokhimiia · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Chemical science · 2018
    Article
  19. Review
  20. Iterative optimization yields Mcl-1-targeting stapled peptides with selective cytotoxicity to Mcl-1-dependent cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Raheleh Rezaei AraghiMIT Department of Biology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States.
Amy E KeatingMIT Department of Biology, 77 Massachusetts Avenue, Cambridge, MA 02139, United States; MIT Department of Biological Engineering, 77 Massachusetts Avenue, Cambridge, MA 02139, United States. Electronic address: keating@mit.edu.

Funding

Analysis and Design of Coiled Coil PartneringR01GM067681 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KEATING, AMY E · 2004 to 2012
$2.9M
Computationally guided design of helical peptide interaction reagentsR01GM110048 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KEATING, AMY E · 2014 to 2020
$1.8M
Analysis and design of interaction specifically in proteins regulating apoptosisR01GM084181 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KEATING, AMY E · 2008 to 2011
$1.2M
NIGMS NIH HHS R01 GM067681NIGMS NIH HHS R01 GM084181NIGMS NIH HHS R01 GM110048
6 · The paper itself

Abstract

Short helical peptides combine characteristics of small molecules and large proteins and provide an exciting area of opportunity in protein design. A growing number of studies report novel helical peptide inhibitors of protein-protein interactions. New techniques have been developed for peptide design and for chemically stabilizing peptides in a helical conformation, which frequently improves protease resistance and cell permeability. We summarize advances in peptide crosslinking chemistry and give examples of peptide design studies targeting coiled-coil transcription factors, Bcl-2 family proteins, MDM2/MDMX, and HIV gp41, among other targets.

Indexed as

Drug DesignAnimalsHumansPeptidesProtein BindingProtein Conformation, alpha-HelicalProteinsPeptidesProteins

Identifiers

PMID27123812
PMCPMC5282971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.